Maryann Redlinger, RN
Articles
Irinotecan and UFT/Leucovorin in Patients With Advanced Cancers
James P. Stevenson, MD;Maryann Redlinger, RN;Weijing Sun, MD, FACP;Daniel G. Haller, MD;Peter J. O'dwyer, MD
October 1st 2000The combination of irinotecan and fluorouracil (5-FU) is synergistic when applied to human colon cancer cell lines in vitro and appears to be schedule-dependent: maximal activity occurs when irinotecan is administered prior to 5-FU. In this phase I study, irinotecan is administered in combination with UFT and leucovorin in patients with advanced solid tumors.
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: August 19th 2019 | Updated: November 22nd 2024
A 22-Year-Old Woman With Pain, Tenderness and Swelling in the Breast
Published: July 29th 2015 | Updated: November 22nd 2024
Liver Abnormality in 28-Year-Old Patient
Published: November 8th 2024 | Updated: November 22nd 2024
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
